A study of novel anti-cancer agents in patients with previously untreated NSCLC - MAGELLAN

Inclusion Criteria

• Inclusion Criteria:
• - Histologically or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation
• - No prior chemotherapy or any other systemic therapy for metastatic NSCLC
• - Prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, if progression has occurred >12 months from end of last therapy
• - Known tumor PD-L1 status
• - Tumors that lack activating EGFR mutations and ALK fusions or documented local test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care
• - WHO/ECOG status at 0 or 1 at enrollment
• - Life expectancy of at least 12 weeks
• -Troponin I or T ≤ ULN (per institutional guidelines)
• Exclusion Criteria:
• - Active or prior documented autoimmune or inflammatory disorders
• - History of active primary immunodeficiency
• - Any prior chemotherapy or any other systemic therapy for metastatic NSCLC
• - Untreated CNS metastases